Clinical Trials Logo

Clinical Trial Summary

This study is a multicenter, single-arm, open-label, 24 weeks, and investigator-initiated clinical trial to assess the influence of CYP3A5 polymorphism on liver function abnormality and the trough level change after conversion to Advagraf® in liver transplant recipients.


Clinical Trial Description

All subjects who are liver transplant recipients taking Tacrolimus bid and adaptable to be registered for the study will be classified by expressive or non-expressive CYP3A5 polymorphism genotype and Advagraf® will be administered same dose as Tacrolimus bid der day in 24 weeks.

All subjects should check whether being registered in the hospital based on CYP3A5 polymorphism genotype during screening visit. Registered subjects will visit seven times to the hospital during the study which includes screening visit and adverse reaction, acute rejection, and trough level will be tested during this period. Subjects who are additionally agreed for PK study will be hospitalized with the state of Tacrolimus bid therapy one day ago before taking IP. On the first day of hospitalization, his/her blood will be collected. At week 1 (plus seven days) after conversion to Advagraf®, his/her blood will be collected for PK analysis. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02882113
Study type Interventional
Source Seoul National University Hospital
Contact Sung-Eun Kim
Phone +82-10-6361-7139
Email loveu0322@gmail.com
Status Recruiting
Phase Phase 4
Start date July 2016
Completion date December 2018

See also
  Status Clinical Trial Phase
Completed NCT02754219 - Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction Phase 1
Terminated NCT01079104 - Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units N/A
Recruiting NCT00553553 - Efficacy of Multimodal Opioid Therapy During Hepatic Resection Surgery N/A
Completed NCT03641872 - A Validation Cohort for ACLF Diagnosis and Prognosis
Completed NCT03371537 - Study of Hemodynamic Conditions Measured During Hepatectomy
Not yet recruiting NCT05559242 - Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients Phase 1
Recruiting NCT02473601 - Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis Phase 2
Completed NCT01000337 - Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol N/A
Completed NCT03155984 - Optimizing HBV Management During Anti-CD20 Antibodies
Recruiting NCT06126419 - Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration N/A
Completed NCT03515980 - An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function Phase 1
Completed NCT01338714 - The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function Phase 3
Completed NCT02005744 - A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Phase 1
Completed NCT01367522 - Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function Phase 1
Recruiting NCT03805139 - Role of Ajwa Derived Polyphenols in Dyslipidaemias N/A
Enrolling by invitation NCT05082077 - Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Completed NCT02949505 - Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation N/A
Completed NCT02991339 - The Effects of Dexamethasone Administration on Jaundice Following Liver Resection Phase 2/Phase 3
Completed NCT02992639 - Weight Loss Effect on Circulating Liver Enzymes N/A
Recruiting NCT05793203 - Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients